Preclinical Development of Molecularly Targeted Agents in Oncology
作者： Joseph E. Tomaszewski , James H. Doroshow
DOI: 10.1007/978-1-59745-337-0_31
关键词:
摘要: The discovery and development of molecularly targeted agents to treat cancer requires a new paradigm for moving novel drugs more rapidly through the pipeline into clinical setting. We must clearly understand pharmacology (kinetics dynamics) each agent effect drug on its purported target(s). To optimize process, validated pharmacokinetic (PK) pharmacodynamic (PD) assays be available used in preclinical setting before advancing trials first in-human studies. present discovery-developmental continuum that supports performing human pharmacologic studies earlier shorten time from target evaluation.
springer.com
sci-hub.st 参考文章(33)
Brian J. Druker, Moshe Talpaz, Debra J. Resta, Bin Peng, Elisabeth Buchdunger, John M. Ford, Nicholas B. Lydon, Hagop Kantarjian, Renaud Capdeville, Sayuri Ohno-Jones, Charles L. Sawyers, Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia The New England Journal of Medicine. ,vol. 344, pp. 1031- 1037 ,(2001) , 10.1056/NEJM200104053441401
H.H Fiebig, A Maier, A.M Burger, Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. European Journal of Cancer. ,vol. 40, pp. 802- 820 ,(2004) , 10.1016/J.EJCA.2004.01.009
Tune Bm, Griswold Wr, Mendoza Sa, Sibley Rk, Kirpekar R, Reznik Vm, Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clinical Nephrology. ,vol. 43, pp. 84- 88 ,(1995)
L.R. Kelland, “Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development European Journal of Cancer. ,vol. 40, pp. 827- 836 ,(2004) , 10.1016/J.EJCA.2003.11.028
S Marsoni, C K Grieshaber, Relation of preclinical toxicology to findings in early clinical trials. Cancer treatment reports. ,vol. 70, pp. 65- 72 ,(1986)
K Hansen, C Khanna, Spontaneous and genetically engineered animal models: use in preclinical cancer drug development European Journal of Cancer. ,vol. 40, pp. 858- 880 ,(2004) , 10.1016/J.EJCA.2003.11.031
Franco M. Muggia, "Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy" ,(2011)
Joseph E. Tomaszewski, Adaline C. Smith, Joseph M. Covey, Susan J. Donohue, Julie K. Rhie, Karen M. Schweikart, CHAPTER 17 – RELEVANCE OF PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TO PHASE I TRIAL EXTRAPOLATION TECHNIQUES: RELEVANCE OF ANIMAL TOXICOLOGY Anticancer Drug Development. pp. 301- 328 ,(2002) , 10.1016/B978-012072651-6/50018-8
M.C. Bibby, Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages European Journal of Cancer. ,vol. 40, pp. 852- 857 ,(2004) , 10.1016/J.EJCA.2003.11.021
Joseph E. Tomaszewski, Multi-species toxicology approaches for oncology drugs: the US perspective. European Journal of Cancer. ,vol. 40, pp. 907- 913 ,(2004) , 10.1016/J.EJCA.2003.11.024